The offering is dilutive and priced at market with no premium, signaling that the company needed to raise capital urgently. Monitor for potential further dilution if the underwriters exercise the greenshoe option. The stock may face near-term selling pressure as the market absorbs the new shares.
Price Chart
Executive Summary
Jade Biosciences priced a public offering of 10,000,000 shares of common stock at $15.00 per share, with an underwriter option for an additional 1,500,000 shares. Net proceeds to the company are expected to be approximately $140.3 million ($161.5 million if the option is fully exercised). The offering represents approximately 17% dilution based on the $868M pre-offering market cap, and the stock is trading at the offering price, signaling no premium.
Key Facts
- 10,000,000 shares offered at $15.00 per share, raising $150M gross proceeds
- Underwriters have a 30-day option to purchase up to 1,500,000 additional shares
- Net proceeds expected to be ~$140.3M (~$161.5M if option fully exercised)
- Offering priced at $14.10 per share to underwriters, representing a 6% discount to the public price
- Offering expected to close June 5, 2026
- Proceeds to fund clinical trials, preclinical studies, manufacturing, R&D, and working capital
- Lock-up agreements in place for directors, executive officers, and Fairmount Funds affiliates for 60 days post-offering
Financial Impact
Dilution of approximately 17% based on pre-offering market cap of $868M and gross proceeds of $150M. Net proceeds of ~$140.3M represent ~16% of pre-offering market cap.
Risk Factors
- Dilution of approximately 17% for existing shareholders
- Potential for additional dilution if underwriters exercise the 1.5M share option
- Proceeds used for clinical-stage pipeline with no approved products, high cash burn risk
- Stock trading at offering price suggests no immediate demand premium
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-257733 |
| Document: d103726d8k.htm | 0001193125-26-257733 |
| Document: d103726dex51.htm | 0001193125-26-257733 |
| Document: d103726dex992.htm | 0001193125-26-257733 |
| Document: d103726dex991.htm | 0001193125-26-257733 |
| Document: 0001193125-26-257733-index-headers.html | 0001193125-26-257733 |
| Document: 0001193125-26-257733-index.html | 0001193125-26-257733 |
| Document: 0001193125-26-257733.txt | 0001193125-26-257733 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 8-K | $14.05 $13.77 | ▼ −1.99% | ▼ −3.91% | $14.50 (+3.20%) |
Aug 10, 2026 11w ago | 8-K | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.50 (−33.27%) |
Aug 10, 2026 11w ago | Press Release | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.50 (−33.27%) |
Jun 5, 2026 20w ago | Press Release | $14.98 $16.10 | ▼ −7.48% | ▼ −5.37% | $14.50 (+3.20%) |
Jun 4, 2026 20w ago | 8-K | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.50 (+14.40%) |
Jun 4, 2026 20w ago | 424B5 | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.50 (+14.40%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 3, 2026 20w ago | 424B5 | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 1, 2026 21w ago | 8-K | $18.59 $16.94 | ▼ −8.88% | ▼ −6.13% | $14.50 (−22.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers